プロの翻訳者、企業、ウェブページから自由に利用できる翻訳レポジトリまで。
ispitivanja kancerogenosti sa simeprevirom nisu bila provedena.
carcinogenicity studies with simeprevir have not been conducted.
最終更新: 2017-04-26
使用頻度: 1
品質:
iskustvo u ljudi s predoziranjem simeprevirom je ograničeno.
human experience of overdose with simeprevir is limited.
最終更新: 2017-04-26
使用頻度: 1
品質:
ne preporučuje se istodobna primjena pojačane preziste sa simeprevirom.
it is not recommended to co-administer boosted prezista and simeprevir.
最終更新: 2017-04-26
使用頻度: 1
品質:
nema prikladnih i dobro kontroliranih ispitivanja sa simeprevirom u trudnica.
there are no adequate and well-controlled studies with simeprevir in pregnant women.
最終更新: 2017-04-26
使用頻度: 1
品質:
uključuje 4 bolesnika liječena simeprevirom koji su doživjeli relaps nakon svr12.
includes 4 simeprevir-treated patients who experienced relapse after svr12.
最終更新: 2017-04-26
使用頻度: 1
品質:
tablica 11: ispitivanja provedena sa simeprevirom + sofosbuvirom: populacija i sažetak dizajna ispitivanja
table 11: studies conducted with simeprevir + sofosbuvir: population and summary of study design
最終更新: 2017-04-26
使用頻度: 1
品質:
osip ili pruritus stupnja 3 pojavio se u 0,5% odnosno 0,1% bolesnika liječenih simeprevirom.
grade 3 rash or pruritus occurred in 0.5% and 0.1% of simeprevir-treated patients, respectively.
最終更新: 2017-04-26
使用頻度: 1
品質:
nastale ns3 supstitucije aminokiselina bile su slične onima zabilježenim u bolesnika koji nisu postigli svr nakon liječenja simeprevirom u kombinaciji s peginterferonom alfa i ribavirinom.
the emerging ns3 amino acid substitutions were similar to those observed in patients who did not achieve svr following treatment with simeprevir in combination with peginterferon alfa and ribavirin.
最終更新: 2017-04-26
使用頻度: 1
品質:
obrasci supstitucija aminokiselina, specifični za podtip hcv genotipa 1, koji su proizašli iz liječenja simeprevirom bili su uočeni u bolesnika koji nisu postigli svr.
hcv genotype 1 subtype-specific patterns of simeprevir treatment-emergent amino acid substitutions were observed in patients not achieving svr.
最終更新: 2017-04-26
使用頻度: 1
品質:
tablica 17: ispitivanja provedena sa simeprevirom + peginterferonom alfa + ribavirinom: populacija i sažetak dizajna ispitivanja
table 17: studies conducted with simeprevir + peginterferon alfa + ribavirin: population and summary of study design
最終更新: 2017-04-26
使用頻度: 1
品質:
poremećaji laboratorijskih nalaza koji su proizašli tijekom liječenja te su uočeni s većom incidencijom u bolesnika liječenih simeprevirom nego u bolesnika liječenih placebom, peginterferonom alfa i ribavirinom prikazani su u tablici 7.
treatment-emergent laboratory abnormalities that were observed at a higher incidence in simeprevir-treated patients than in patients treated with placebo, peginterferon alfa and ribavirin are given in table 7.
最終更新: 2017-04-26
使用頻度: 1
品質:
doza simeprevira u ovom ispitivanju interakcija bila je 50 mg kada se istodobno primjenjivao u kombinaciji s darunavirom/ritonavirom, u usporedbi sa 150 mg u skupini liječenoj samim simeprevirom.
the dose of simeprevir in this interaction study was 50 mg when co-administered in combination with darunavir/ritonavir, compared to 150 mg in the simeprevir alone treatment group.
最終更新: 2017-04-26
使用頻度: 1
品質:
populacijska farmakokinetika procjenjuje izloženost simeprevira što je usporedivo među bolesnicima bijele i crne/afro-američke rase inficiranima hcv-om liječenih simeprevirom u kombinaciji s peginterferonom alfa i ribavirinom.
population pharmacokinetic estimates of exposure of simeprevir were comparable between caucasian and black/african american hcv infected patients treated with simeprevir in combination with peginterferon alfa and ribavirin.
最終更新: 2017-04-26
使用頻度: 1
品質:
dob (18-73 godina) nije klinički značajno utjecala na farmakokinetiku simeprevira, temeljeno na populacijskoj farmakokinetičkoj analizi (n = 21, dob iznad 65 godina) bolesnika inficiranih hcv-om koji su liječeni simeprevirom.
age (18-73 years) had no clinically meaningful effect on the pharmacokinetics of simeprevir based on a population pharmacokinetic analysis (n = 21, age above 65 years) of hcv infected patients treated with simeprevir.
最終更新: 2017-04-26
使用頻度: 1
品質: